Mersana Therapeutics (United States)

Recent papers from Mersana Therapeutics (United States)

1. Emiltatug ledadotin (Emi-Le), a B7-H4–directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.Journal of Clinical Oncology · 2026
2. Abstract PS1-08-23: Emiltatug Ledadotin (Emi-Le): A B7-H4-Directed Dolasynthen Antibody-Drug Conjugate (ADC) Being Investigated in Phase 1 Dose Expansion in Patients with Triple Negative Breast Cancer who Received at Least One Prior Topoisomarase-1 Inhibitor ADCClinical Cancer Research · 2026
3. PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐HydroxypropylamideCPT Pharmacometrics & Systems Pharmacology · 2025
4. Constructing the cure: engineering the next wave of antibody and cellular immune therapiesJournal for ImmunoTherapy of Cancer · 2025
5. XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune CellsClinical Cancer Research · 2025
6. A cross-species assessment of in silico prediction methods of steady-state volume of distribution using Simcyp simulatorsJournal of Pharmaceutical Sciences · 2024
7. Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN Loss2024
8. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial2024
9. Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responsesNature Communications · 2024
10. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group StudyJournal of Clinical Oncology · 2024
11. Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCsCancer Research · 2024
12. #168 UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)2024
13. 559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)2024
14. Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug ConjugatesMolecular Cancer Therapeutics · 2024
15. Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology StudiesToxicologic Pathology · 2024
16. Microglial roles in Alzheimer's disease: An agent‐based model to elucidate microglial spatiotemporal response to beta‐amyloidCPT Pharmacometrics & Systems Pharmacology · 2023
17. Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody RatiosMolecular Cancer Therapeutics · 2023
18. Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug ConjugatesJournal of Medicinal Chemistry · 2023
19. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of CancerMolecular Cancer Therapeutics · 2023
20. Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line TherapyJCO Clinical Cancer Informatics · 2023